An investor offloaded $104 million worth of Nuvalent shares as the cancer drug company surged almost 30%.

Vestal Point Capital Sells Nuvalent Shares Worth Over $100 Million

On February 17, 2026, Vestal Point Capital reported to the SEC that it had divested 1,054,000 shares of Nuvalent (NASDAQ:NUVL), a transaction valued at approximately $103.93 million based on the average price for the quarter.

Details of the Transaction

According to the SEC filing dated February 17, 2026, Vestal Point Capital’s sale of Nuvalent shares led to a $90.50 million decrease in the fund’s quarter-end position, reflecting both the sale and changes in share value during the period.

Portfolio Impact and Key Holdings

• Following the sale, Nuvalent now represents less than 1% of Vestal Point Capital’s 13F assets under management.
• Major holdings after this adjustment include:
  • NASDAQ:ABVX: $256.22 million (9.4% of AUM)
  • NASDAQ:ACLX: $190.71 million (7.0% of AUM)
  • NASDAQ:TERN: $181.80 million (6.7% of AUM)
  • NASDAQ:BMRN: $178.29 million (6.5% of AUM)
  • NYSE:GMED: $111.32 million (4.1% of AUM)
• As of February 17, 2026, Nuvalent’s share price stood at $102.24, marking a 29.11% increase over the past year—outpacing the S&P 500’s roughly 19% gain in the same timeframe.

Nuvalent Company Snapshot

About Nuvalent

• Nuvalent is focused on developing targeted therapies for cancer that are in the clinical stage. Its leading drug candidates include NVL-520, a ROS1-selective inhibitor, and NVL-655, an ALK-selective inhibitor—both designed to overcome resistance and address brain metastases in cancer treatment.
• The company’s primary customers are oncologists, healthcare professionals, and biopharma partners treating patients with resistant or hard-to-treat cancers.
• Nuvalent is based in Cambridge, Massachusetts, and was founded in 2017.

Specializing in precision oncology, Nuvalent is advancing a pipeline of next-generation therapies aimed at overcoming resistance mutations and central nervous system involvement in cancer. The company’s approach leverages expertise in small-molecule drug design, with a focus on moving innovative candidates through early clinical development milestones.

Implications for Investors

Biotechnology portfolios can shift rapidly as clinical progress and new opportunities arise. When investors reallocate funds away from a promising biotech, it doesn’t always indicate a lack of faith—it may simply reflect a search for the next big catalyst.

Nuvalent is approaching a significant period, with management preparing for a potential FDA decision on zidesamtinib for previously treated ROS1-positive lung cancer, expected in September. Additionally, the company intends to seek regulatory review for neladalkib, another oncology candidate, targeting ALK-positive lung cancer.

Financially, Nuvalent reported around $1.4 billion in cash and investments at the end of 2025, providing resources to operate through 2029. The company’s future now depends on its ability to achieve key regulatory milestones and turn its scientific advances into approved therapies.

Is Now the Time to Invest in Nuvalent?

Before deciding to invest in Nuvalent, consider the following:

The Motley Fool Stock Advisor team recently revealed their picks for the 10 best stocks to buy now—and Nuvalent was not among them. The selected stocks are believed to have strong growth potential in the years ahead.

For example, when Netflix was recommended on December 17, 2004, a $1,000 investment would now be worth $514,000. Similarly, a $1,000 investment in Nvidia from April 15, 2005, would have grown to $1,105,029.

Currently, Stock Advisor boasts an average return of 930%, far surpassing the S&P 500’s 187%. Don’t miss the latest top 10 recommendations, available with Stock Advisor, and join a community of investors focused on long-term growth.

*Stock Advisor performance as of March 16, 2026.

Jonathan Ponciano does not hold positions in any of the mentioned stocks. The Motley Fool owns shares of and recommends Globus Medical, and also recommends BioMarin Pharmaceutical. For more information, see The Motley Fool’s disclosure policy.